CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CAR-T)

CD19/CD22-targeted CAR-T · Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CAR-T), covering 2023-11-29 to 2023-11-29. Get the full timeline:

Most recent: Clinical Trial Update: CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia. [Phase 1, Phase 2]

See pricing